Table 2.
In vivo outcome measures
| Study | Number of patients | Treatment outcome (n. %) | |||||
| Included | Drop out* | Analysed | ACPR | LTF | LPF | LCF | |
| AL2002† | 55 | 10(4) | 45 | 32(71.1) | 13(28.9) | 2(4.4) | 11(24.5) |
| AL2003† | 80 | 6(3) | 74 | 64(86.5) | 10(13.5) | 6(8.1) | 4(5.4) |
| AM2003‡ | 55 | 3(0) | 52 | 48(92.3) | 4(7.7) | 3(5.7) | 1(2) |
| AM2004‡ | 85 | 4(1) | 81 | 75(92.6) | 6(7.4) | 0(0) | 6(7.4) |
ACPR. Adequate Clinical and Parasitological Response; LTF. Late Treatment Failure;
LCF. Late Clinical Failure; LPF. Late Parasitological Failure; LTF = LCF + LPF.
*Number between parenthesis indicates the number Plasmodium vivax infections
†Artemether 20 mg/kg and lumefantrine 120 mg/kg
‡Artesunate 12 mg/kg and mefloquine 25 mg/kg